EvaniewN., NoonanV.K., FallahN., KwonB.K., RiversC.S., AhnH., BaileyC.S., ChristieS.D., FourneyD.R., HurlbertR.J., LinassiA.G., FehlingsM.G., DvorakM.F., and RHSCIR Network. (2015). Methylprednisolone for the treatment of patients with acute spinal cord injuries: a propensity score-matched cohort study from a Canadian multi-center spinal cord injury registry. J. Neurotrauma, 32, 1674–1683.
2.
DvorakM.F., NoonanV.K., FallahN., FisherC.G., RiversC.S., AhnH., TsaiE.C., LinassiA.G., ChristieS.D., AttabibN., HurlbertR.J., FourneyD.R., JohnsonM.G., FehlingsM.G., DrewB., BaileyC.S., PaquetJ., ParentS., TownsonA., HoC., CravenB.C., GagnonD., TsuiD., FoxR., Mac-ThiongJ.M., and KwonB.K. (2014) Minimizing errors in acute traumatic spinal cord injury trials by acknowledging the heterogeneity of spinal cord anatomy and injury severity: an observational Canadian cohort analysis. J. Neurotrauma, 31, 1540–1547.
3.
HurlbertR.J., and MoultonR. (2002). Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement. Can. J. Neurol. Sci., 29, 236–239.
4.
EvaniewN., Belley-CôtéE.P., FallahN., NoonanV.K., RiversC.S., and DvorakM.F. (2016). Methylprednisolone for the treatment of patients with acute spinal cord injuries: a systematic review and meta-analysis. J. Neurotrauma, 33, 468–481.
